Abstract 57P
Background
Metabolic reprogramming is considered as a hallmark of cancer and is clinically exploited as a target for therapy. The E2F transcription factor-1 (E2F1) regulates metabolic pathways and operates as an oncogene or tumor suppressor as evident by the observation that E2f1-knockout mice develop spontaneous tumors. This discrepancy warrants a detailed investigation how E2F1’s metabolic functions control cellular proliferation and tumor growth.
Methods
Taking advantage of mouse embryonic fibroblasts (MEFs), isolated from E2f1-wild-type (E2f1+/+) and E2f1-knock-out (E2f1-/-) mice as well as transcriptomic profiles (TCGA Pan-cancer study), we investigated the biological outcomes of altered E2F1 expression on glutamine metabolism.
Results
Our data indicate that E2F1 binds the promoter of several glutamine metabolic genes. Interestingly, the gene expression levels of genes in the glutamine metabolic pathway are strongly increased in mouse embryonic fibroblasts lacking E2F1 compared to E2f1+/+ MEFs. In addition, we confirm that E2f1-/- MEFs are more efficient in metabolizing glutamine and producing precursors for proliferation. Mechanistically, we observe a co-occupancy of E2F1 and MYC on glutamine metabolic promoters, increased MYC binding after E2F1 depletion and silencing of MYC decreases the expression of glutamine metabolic genes in E2f1-/- MEFs, suggesting that MYC contributes to increased glutamine metabolic gene expression in E2f1-/- MEFs. These features have also been observed in human patient samples in a screen of 21 different cancer types and showed high relevance in uterine carcinosarcoma and soft tissue sarcomas.
Conclusions
These results confirm increased proliferation upon E2F1 loss, which is dependent on glutamine metabolism. Altogether, our results suggest that E2F1 is a regulator of glutamine metabolism and highlights potentially new targets for cancer interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Pichler and L. Fajas.
Funding
Austrian Science Fund (J4597-B), Swiss National Science Foundation grant (31003A_143369).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
52P - Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
Presenter: Thi Thuy Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
Presenter: Francesco Bertoni
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
Presenter: Tina Jost
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
Presenter: Martin Hohenegger
Session: Cocktail & Poster Display session
Resources:
Abstract
56P - Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
Presenter: Kelsey Gauthier
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
Presenter: Maryam Arshad
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
Presenter: Jamie Rijmers
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
Presenter: Emilien Ezine
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
Presenter: Jiyoon Jung
Session: Cocktail & Poster Display session
Resources:
Abstract
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract